Episode 18: A Between the Biotech Waves conversation with Ram Aiyer, CEO of RNA base editing company Korro Bio
Between the Biotech Waves
00:00
The Complexity of the Drug Product That You Need to Build
The team has done a great job in identifying where is the rate limiting stuff there. That's really what drives into which targets, which indications that you can really go after and prosecute rather than everything. The kinetics that you've got to drive to be able to get what you need at your target site always blows my mind. For this, when you look at it for genome editing overall, insertions, zinc fingers, it really is quite staggering what needs to be done and the fact that it happens. It is amazing that it actually happens within the cell.
Transcript
Play full episode
